{'fraction_non_alphanumeric': 0.02219626168224299, 'fraction_numerical': 0.0011682242990654205, 'mean_word_length': 5.856, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Competition Heats Up in Rheumatoid Arthritis and Other Autoimmune Conditions.

Rheumatoid arthritis (RA) is a systemic, inflammatory form of arthritis that results in joint inflammation, pain, swelling, and stiffness.1 Although new treatment strategies that focus on early diagnosis, aggressive treatment, and consistent monitoring have helped many patients achieve their goals, RA continues to present clinical and economic challenges to patients, physicians, and payers. Clinically favorable and cost-effective treatments must focus on the prevention of disease progression and on improving patients’ quality of life and productivity. With the wide variety of treatment options currently available and more in the pipeline, payers are faced with the challenge of identifying the most clinically and economically effective allocation of treatments for RA.